# Mirvetuximab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mirvetuximab

> The FDA approved mirvetuximab, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on Nov 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is mirvetuximab FDA approved?

Yes. The FDA approved mirvetuximab, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on Nov 2022. Press release filed with the SEC (EX-99): "MIRASOL Phase 3 (N=453)56 Mirvetuximab soravtansine vs chemotherapy FDA approved for FR⍺-positive PROC Nov 2022 ADC, antibody-drug conjugate; CI, confidence interval; CT, chemotherapy; FR⍺, folate receptor alpha; mDoR, duration of response; MIRV, mirvetuximab soravtansine; mo, months; mOS, median overall survival; mPFS, median progression-free survival; ORR, overall response rate; PROC, platinum-resistant ovarian cancer." [Calendar and source filings](https://sec-api.dev/pdufa/mirvetuximab)

Source: Press release filed with the SEC (EX-99), accession 0001193125-25-199857, https://www.sec.gov/Archives/edgar/data/1699382/000119312525199857/d90438dex991.htm (retrieved 2026-11-12). Last confirmed 2025-09-10. Cite: https://sec-api.dev/pdufa/mirvetuximab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | mirvetuximab |
| Codes |  |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | folate receptor alpha |
| Modality | antibody |
| FDA designations | priority review |

## Timeline

### Nov 2022: FDA approval

- Status: completed, approved. Date confidence: month. Stage: 3.
- First seen 2025-09-10, last confirmed 2025-09-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-199857): "MIRASOL Phase 3 (N=453)56 Mirvetuximab soravtansine vs chemotherapy FDA approved for FR⍺-positive PROC Nov 2022 ADC, antibody-drug conjugate; CI, confidence interval; CT, chemotherapy; FR⍺, folate receptor alpha; mDoR, duration of response; MIRV, mirvetuximab soravtansine; mo, months; mOS, median overall survival; mPFS, median progression-free survival; ORR, overall response rate; PROC, platinum-resistant ovarian cancer." https://www.sec.gov/Archives/edgar/data/1699382/000119312525199857/d90438dex991.htm

### Jan 2026: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: folate receptor alpha.
- First seen 2026-05-26, last confirmed 2026-05-26.
- Press release filed with the SEC (EX-99) (accession 0001395064-26-000162): "Development code: TAK-853 / Generic name: mirvetuximab soravtansine - In January 2026, Takeda announced it submitted the New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) for mirvetuximab soravtansine for the treatment of folate receptor alpha (FRα)-positive, platinum- resistant recurrent ovarian cancer (PROC) in Japan." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mirvetuximab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Mirvetuximab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mirvetuximab

```bibtex
@misc{secapidev_pdufa_mirvetuximab_20261116,
  title        = {Mirvetuximab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mirvetuximab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mirvetuximab_20261116","title":"Mirvetuximab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mirvetuximab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
